INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Integra LifeSciences Holdings Corporation

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 10:13:29 2024-05-15 am EDT			5-day change	1st Jan Change
26.3 ^USD	-0.55%		+6.26%	-39.22%

May. 07	Truist Cuts Price Target on Integra LifeSciences Holdings to $25 From $37, Keeps Hold Rating	MT
May. 07	Wells Fargo Downgrades Integra LifeSciences Holdings to Equalweight From Overweight, Cuts Price Target to $25 From $45	MT

Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023.

October 25, 2023 at 04:22 pm EDT

From July 18, 2023 to September 30, 2023, the company has repurchased 2,296,739 shares, representing 2.82% for $88.35 million. With this, the company has completed the repurchase of 2,296,739 shares, representing 2.82% for $88.35 million under the buyback announced on July 27, 2023.

Latest news about Integra LifeSciences Holdings Corporation

Truist Cuts Price Target on Integra LifeSciences Holdings to $25 From $37, Keeps Hold Rating	May. 07	MT
Wells Fargo Downgrades Integra LifeSciences Holdings to Equalweight From Overweight, Cuts Price Target to $25 From $45	May. 07	MT
Oppenheimer Downgrades Integra LifeSciences Holdings to Perform From Outperform	May. 07	MT
Integra LifeSciences Shares Drop to Record Low on Unexpected Loss, Boston Facility Audit Findings	May. 06	DJ
Transcript : Integra LifeSciences Holdings Corporation, Q1 2024 Earnings Call, May 06, 2024	May. 06
Integra LifeSciences Q1 Adjusted Earnings, Revenue Fall; Updates 2024 Outlook	May. 06	MT
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Integra LifeSciences Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Reports Q1 Revenue $368.9M, vs. Street Est of $362M	May. 06	MT
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q1 EPS $0.55, vs. Street Est of $0.55	May. 06	MT
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024	May. 06	CI
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target	Apr. 03	MT
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target is $38	Apr. 03	MT
Integra LifeSciences Completes Acquisition of Acclarent	Apr. 01	MT
Integra LifeSciences Holdings Corporation acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.	Mar. 31	CI
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases	Mar. 11	CI
Integra Lifesciences Holdings Insider Sold Shares Worth $305,492, According to a Recent SEC Filing	Mar. 08	MT
Truist Securities Cuts Price Target on Integra LifeSciences Holdings to $41 From $46, Maintains Hold Rating	Mar. 01	MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023.	Feb. 28	CI
Integra LifeSciences Shares Drop Following Q4 Results	Feb. 28	MT
Integra LifeSciences Seeks Acquisitions	Feb. 28	CI
Transcript : Integra LifeSciences Holdings Corporation, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Integra LifeSciences' Q4 Adjusted Earnings, Revenue Decline	Feb. 28	MT
Integra LifeSciences Holdings Corporation Announces the Retirement of Jan De Witte as Chief Executive Officer	Feb. 28	CI

Chart Integra LifeSciences Holdings Corporation

Duration

Period

Chart Integra LifeSciences Holdings Corporation

More charts

Company Profile

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Integra LifeSciences Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.44 USD

Average target price

33.8 USD

Spread / Average Target

+27.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION	-39.22%	2.08B
ABBOTT LABORATORIES	-5.26%	181B
MEDTRONIC PLC	+2.40%	112B
BECTON, DICKINSON AND COMPANY	-3.72%	67.92B
DEXCOM, INC.	+3.26%	50.1B
CENCORA, INC.	+8.33%	44.27B
HOYA CORPORATION	+9.39%	40.41B
METTLER-TOLEDO INTERNATIONAL, INC.	+24.32%	31.95B
WEST PHARMACEUTICAL SERVICES, INC.	+0.25%	25.82B
TERUMO CORPORATION	+17.27%	25.29B

Other Medical Equipment, Supplies & Distribution